Additionally, IL-5, which is associated with eosinophilia and VLS induced by high-dose IL-2, did not significantly change in response to SAR’245 treatment alone or in combination with pembrolizumab or nivolumab (8). The gene discussed is IL5; the disease is Increased total eosinophil count.